Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21196404 | 0.79 | MAOB (0.44) | MAOBIDO1AGXTLOXL2MAPK14 | |
| Hydrochloric Acid SCHEMBL25408330 | 0.77 | MAOB (0.45) | MAOBIDO1AGXTLOXL2MAPK14 | |
| Hydrochloric Acid SCHEMBL29506808 | 0.77 | MAOB (0.45) | MAOBIDO1AGXTLOXL2MAPK14 | |
| SCHEMBL2007285 | 0.77 | LOXL2 (0.48) | MAOBIDO1AGXTLOXL2 | |
| SCHEMBL15054210 | 0.73 | MAOB (0.40) | MAOBIDO1AGXTLOXL2MAPK14 | |
| SCHEMBL30523636 | 0.73 | MAOB (0.40) | MAOBIDO1AGXTLOXL2MAPK14 | |
| SCHEMBL18562850 | 0.72 | LOXL2 (0.43) | MAOBIDO1AGXTLOXL2CSNK2A1 | |
| SCHEMBL1695325 | 0.72 | CSNK2A1 (0.45) | MAOBLOXL2MAPK14CSNK2A1 | |
| SCHEMBL2440368 | 0.71 | CSNK2A1 (0.45) | LOXL2ROCK2ROCK1CSNK2A1AKT1 | |
| SCHEMBL25404947 | 0.71 | RORC (0.38) | IDO1AGXTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509423-B2 | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | ALCHEMEDICINE, INC. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20230295091-A1 | Compound, Aldehyde Dehydrogenase 2 Activating Agent, Pharmaceutical Composition, and Therapeutic and/or Prophylactic Drug | ALCHEMEDICINE, INC. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295091-A1 | Compound, Aldehyde Dehydrogenase 2 Activating Agent, Pharmaceutical Composition, and Therapeutic and/or Prophylactic Drug | ALCHEMEDICINE, INC. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295091-A1 | Compound, Aldehyde Dehydrogenase 2 Activating Agent, Pharmaceutical Composition, and Therapeutic and/or Prophylactic Drug | ALCHEMEDICINE, INC. (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4238964-A1 | COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND TREATMENT AND/OR PREVENTATIVE DRUG | Alchemedicine, Inc. (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-4238964-A1 | COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND TREATMENT AND/OR PREVENTATIVE DRUG | Alchemedicine, Inc. (JP) | 2023-09-06 | — | — | EP | disclosed |
| CN-116348449-A | Compounds, acetaldehyde dehydrogenase 2 activators, pharmaceutical compositions, and therapeutic and/or prophylactic agents | 亚克医药株式会社 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022092310-A1 | COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND TREATMENT AND/OR PREVENTATIVE DRUG | 株式会社アークメディスン | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509423-B2 | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | ALDH2, ALDH1A1, ADH1A | MAOB 1320/4885IDO1 1126/4885AGXT 884/4885 |
| US-20230295091-A1 | Compound, Aldehyde Dehydrogenase 2 Activating Agent, Pharmaceutical Composition, and Therapeutic and/or Prophylactic Drug | ALDH2, ALDH1A1, ALDH3A1 | MAOB 391/4885IDO1 1410/4885AGXT 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.